Exciting Developments in Ovarian Cancer Treatment
New Data Highlight Continued Potential of Radspherin to Prevent Disease Progression
Oncoinvent ASA, a pioneering radiopharmaceutical company, has recently shared promising results from its innovative treatment for patients suffering from recurrent ovarian cancer. The trial, which focused on Radspherin®, a treatment designed to target cancer spread within the peritoneal cavity, demonstrated encouraging efficacy in a clinical study.
Positive Results from the Phase 1 Trial
The clinical trial, known as RAD-18-001, evaluates the application of Radspherin® in patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The treatment employs radium-224, an alpha-emitting radionuclide, to precisely target micro-metastases after surgery.
In this Phase 1 trial, a total of 21 patients were enrolled, with 10 patients receiving the highest recommended dose of 7 MBq of Radspherin®. The data collected during a final 24-month follow-up revealed that only 1 out of 10 patients experienced recurrence of peritoneal cancer, indicating a remarkable recurrence rate of just 10% among this group. In comparison, it is estimated that about 55-60% of patients undergoing standard care would likely see disease recurrence at this stage.
Reassessing Treatment Efficiency
While there were two additional patients with metastases detected in lymph nodes outside the peritoneum, the overall recurrence rate sat at 30%. Dr. Luis Chiva, Principal Investigator from the Clinica Universidad de Navarra, highlighted the significance of these findings. "These results are truly encouraging and hint at a brighter future for patients, suggesting that Radspherin® could have the potential to extend lifespans and improve quality of life for many who face the harsh realities of ovarian cancer recurrence,” stated Dr. Chiva.
Oncoinvent's Commitment to Innovation
Following these promising results, Oystein Soug, the CEO of Oncoinvent, expressed his gratitude towards the patients and investigators involved in the study. He affirmed the timely progress and his company's dedication to further develop Radspherin® into a standard treatment option for patients with peritoneal metastases.
Oncoinvent operates at the forefront of biotechnology, utilizing the latest technology in their state-of-the-art facilities in Oslo. With a team of approximately 40 dedicated professionals, they strive to make significant advancements in cancer treatment.
Understanding Radspherin®
Radspherin® is a unique investigational radiopharmaceutical treatment that aims to tackle cancers that have already spread to body cavities. This safe and innovative therapy comprises calcium carbonate microparticles infused with radium-224, which releases alpha particles to target cancer effectively. It has shown promise in treating peritoneal carcinomatosis originating from ovarian cancer and colorectal cancer, and is typically administered after the surgical removal of tumors.
Looking Ahead: A Hopeful Future
The results from this trial lay a solid foundation for Oncoinvent's ongoing Phase 2 study, where interim results are anticipated in the near future. The focus on developing treatments that effectively target localized cancers remains a priority for Oncoinvent, reinforcing their mission to improve patient outcomes and expand access to novel therapies in the oncology field.
Frequently Asked Questions
What is Radspherin®?
Radspherin® is an experimental radiopharmaceutical that treats cancers that have spread to body cavities by using radium-224 to target residual cancer cells.
What are the primary results from the Phase 1 trial?
The trial showed that only 10% of patients who received Radspherin® experienced disease recurrence, which is significantly lower than expected in typical cases.
How many patients were included in the RAD-18-001 trial?
A total of 21 patients were enrolled in the RAD-18-001 clinical trial to evaluate the safety and efficacy of Radspherin®.
What is the significance of these trial outcomes?
These trial outcomes are significant as they suggest that Radspherin® may effectively delay disease progression in patients with recurrent ovarian cancer.
What is Oncoinvent's mission?
Oncoinvent aims to develop innovative radiopharmaceutical therapies that target localized metastases while ensuring patient safety and the effectiveness of treatments.
